Document is current
Any future updates will be listed below
-
Authors
Kherbek, Haidara
Itoh, Christopher Y.
Daley, Catherine
Eggers, Scott D.
Hinson, Shannon
Sarker, Pallab
Staff, Nathan P.
Pittock, Sean J.
Dubey, Divyanshu https://orcid.org/0000-0001-6865-9045
-
Funding
Funding for this research was provided by:
State of Minnesota’s David J. Tomassoni ALS Research Grant Program (238183)
- License Information
-
More Information
Article History
Received: 20 March 2024
Accepted: 1 May 2024
First Online: 22 May 2024
Declarations
:
: H.K., C.I. C.D., S.E., S.H., N.S. report no conflicts interest. S.J.P. reports receiving grants, personal fees paid to Mayo Clinic, and nonfinancial support from Alexion Pharmaceuticals, Inc. and MedImmune, Inc./Viela Bio; receiving personal fees from Genentech/Roche, UCB, and Astellas, outside the submitted work; holding patent 8,889,102 (application 12-678350) issued and patent 9,891,219B2 (application 12-573942) issued. D.D. has consulted for UCB, Immunovant, Argenx, Arialys, and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He is a named inventor on filed patent that relates to KLHL11 as marker of autoimmunity and germ cell tumor. He has patents pending for LUZP4-IgG, cavin-4-IgG and SKOR2-IgG as markers of neurological autoimmunity. He has received funding from the DOD (CA210208 & PR220430), David J. Tomassoni ALS Research Grant Program and UCB.
